PT  - JOURNAL ARTICLE
AU  - Martínez-López, Joaquín
AU  - Mateos, María-Victoria
AU  - Encinas, Cristina
AU  - Sureda, Anna
AU  - Hernández-Rivas, José Ángel
AU  - López de la Guía, Ana
AU  - Conde, Diego
AU  - Krsnik, Isabel
AU  - Prieto, Elena
AU  - Grau, Rosalía Riaza
AU  - Gironella, Mercedes
AU  - Blanchard, María Jesús
AU  - Caminos, Nerea
AU  - Fernández de Larrea, Carlos
AU  - Alicia Senin, María
AU  - Escalante, Fernando
AU  - de la Puerta, José Enrique
AU  - Giménez, Eugenio
AU  - Martínez-Barranco, Pilar
AU  - José Mateos, Juan
AU  - Casado, Luis Felipe
AU  - Bladé, Joan
AU  - José Lahuerta, Juan
AU  - De la Cruz, Javier
AU  - San-Miguel, Jesús
TI  - Multiple Myeloma and SARS-CoV-2 Infection: Clinical Characteristics and Prognostic Factors of Inpatient Mortality
AID  - 10.1101/2020.06.29.20142455
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.06.29.20142455
4099  - http://medrxiv.org/content/early/2020/06/30/2020.06.29.20142455.short
4100  - http://medrxiv.org/content/early/2020/06/30/2020.06.29.20142455.full
AB  - There is limited information on the characteristics, pre-admission prognostic factors, and outcomes of patients with multiple myeloma (MM) hospitalized with coronavirus disease 2019 (COVID-19). This retrospective case series investigated characteristics and outcomes of 167 MM patients hospitalized with COVID-19 reported from 73 hospitals within the Spanish Myeloma Collaborative Group network in Spain between March 1 and April 30, 2020. Outcomes were compared with a randomly selected contemporary cohort of 167 age-/sex-matched non-cancer patients with COVID-19 admitted at 6 participating hospitals. Common demographic, clinical, laboratory, treatment, and outcome variables were collected; specific disease status and treatment data were collected for MM patients. Among the MM and non-cancer patients, median age was 71 years and 57% of patients were male in each series, and 75% and 77% of patients, respectively, had at least one comorbidity. COVID-19 clinical severity was moderate-severe in 77% and 89% of patients and critical in 8% and 4%, respectively. Supplemental oxygen was required by 47% and 55% of MM and non-cancer patients, respectively, and 21%/9% vs 8%/6% required non-invasive/invasive ventilation. Inpatient mortality was 34% and 23% in MM and non-cancer patients, respectively. Among MM patients, inpatient mortality was 41% in males, 42% in patients aged >65 years, 49% in patients with active/progressive MM at hospitalization, and 59% in patients with comorbid renal disease at hospitalization, which were independent prognostic factors of inpatient mortality on adjusted multivariate analysis. This case series demonstrates the increased risk and identifies predictors of inpatient mortality among MM patients hospitalized with COVID-19.Key PointsThere is an increased risk of inpatient mortality (34% vs 23%) in MM vs age-/sex-matched non-cancer patients hospitalized with COVID-19.Adverse prognostic factors at admission for inpatient mortality in MM patients include age >65 y, male sex, renal disease, and active MM.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by PETHEMA FoundationAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional Review Board (IRB) of Hospital Universitario 12 de Octubre, Madrid, Spain (n 20/208).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author, upon reasonable request